Press release
Endometriosis Pain Clinical Trials Analysis, 2024: FDA Approvals, Therapies, Pipeline, MOA, ROA and Companies by DelveInsight | FOR 6219, IW-3300, MT-2990, ORIAHNN, Linzagolix, OVAREST, HMI-115, TU2670, OG-6219
Endometriosis Pain Clinical Trials
"Endometriosis Pain Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Endometriosis Pain Market.
The Endometriosis Pain Pipeline report offers a thorough commercial and clinical evaluation of pipeline products, from the pre-clinical development phase to the marketed phase. It includes detailed descriptions of each drug, encompassing its mechanism of action, clinical studies, NDA approvals (if applicable), and product development activities. These activities cover technology, collaborations, mergers and acquisitions, funding, designations, and other product-related details.
Some of the key takeaways from the Endometriosis Pain Pipeline Report: https://www.delveinsight.com/sample-request/endometriosis-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Endometriosis Pain Companies across the globe are diligently working toward developing novel Endometriosis Pain treatment therapies with a considerable amount of success over the years.
• Endometriosis Pain companies working in the treatment market are Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others, are developing therapies for the Endometriosis Pain treatment
• Emerging Endometriosis Pain therapies in the different phases of clinical trials are- FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others are expected to have a significant impact on the Endometriosis Pain market in the coming years.
• In April 2022, A MoH application for HMI-115 was received in the first European nation.
• In March 2020, "A Double-blind Randomised Extension Study to Assess the Long-term Efficacy and Safety of Linzagolix in Subjects With Endometriosis-Associated Pain" was the name of the experiment that Obseva started. This study is prospective, double-blind, and randomised.
• ObsEva has a partnership with Syneos for the American market's commercialization of linzagolix, and a licencing deal with Theramex for the international markets outside of North America, Asia, and Europe.
Endometriosis Pain Overview
Endometriosis Pain is a chronic condition characterized by severe pelvic pain associated with endometriosis, a disorder where tissue similar to the lining inside the uterus grows outside of it. This aberrant tissue can adhere to the ovaries, fallopian tubes, and pelvic lining, causing inflammation, scarring, and adhesions. The pain from endometriosis can be debilitating and is often cyclical, intensifying. However, some women experience constant pain.
Symptoms of endometriosis pain include dysmenorrhea (painful periods), chronic pelvic pain, dyspareunia (pain during intercourse), and pain during bowel movements or urination. It can also be associated with infertility. The exact cause of endometriosis is unknown, but it is thought to involve genetic, immunological, and hormonal factors.
Endometriosis Pain Diagnosis typically involves a combination of pelvic exams, imaging tests such as ultrasounds or MRIs, and laparoscopic surgery, which is the gold standard for confirming endometriosis.
Treatment for endometriosis pain aims to alleviate symptoms and may include hormonal therapies, pain relief medications, and surgical interventions to remove endometrial growths. Additionally, lifestyle modifications, physical therapy, and alternative therapies such as acupuncture may provide relief. Despite various treatment options, managing endometriosis pain can be challenging, and ongoing research is focused on developing more effective therapies to improve the quality of life for affected individuals.
Get a Free Sample PDF Report to know more about Endometriosis Pain Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/endometriosis-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Endometriosis Pain Drugs Under Different Phases of Clinical Development Include:
• FOR 6219: Organon
• IW-3300: Ironwood Pharmaceuticals
• MT-2990: Mitsubishi Tanabe Pharma Corporation
• ORIAHNN (elagolix/estradiol/norethindrone acetate): AbbVie/Neurocrine Biosciences
• Linzagolix (OBE2109): ObsEva/Kissei Pharmaceuticals
• OVAREST (leuprorelin oral): SWK/Enteris BioPharma
• HMI-115: Bayer/Hope Medicine
• TU2670 (NCE-403): Tiumbio
• OG-6219: Organon
• Quinagolide: Ferring Pharmaceuticals
• Linzagolix: ObsEva
Endometriosis Pain Route of Administration
Endometriosis Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Endometriosis Pain Molecule Type
Endometriosis Pain Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Endometriosis Pain Pipeline Therapeutics Assessment
• Endometriosis Pain Assessment by Product Type
• Endometriosis Pain By Stage and Product Type
• Endometriosis Pain Assessment by Route of Administration
• Endometriosis Pain By Stage and Route of Administration
• Endometriosis Pain Assessment by Molecule Type
• Endometriosis Pain by Stage and Molecule Type
DelveInsight's Endometriosis Pain Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Endometriosis Pain product details are provided in the report. Download the Endometriosis Pain pipeline report to learn more about the emerging Endometriosis Pain therapies
https://www.delveinsight.com/sample-request/endometriosis-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Endometriosis Pain Therapeutics Market include:
Key companies developing therapies for Endometriosis Pain are - AbbVie, Neurocrine Biosciences, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, TiumBio Co., Ltd., Mitsubishi Tanabe Pharma, and others.
Endometriosis Pain Pipeline Analysis:
The Endometriosis Pain pipeline report offers comprehensive insights into:
Detailed information about companies developing therapies for Endometriosis Pain, including the total number of therapies each company is working on.
Evaluation of various therapeutic candidates, categorized by early-stage, mid-stage, and late-stage development for Endometriosis Pain treatment.
Key companies focusing on targeted therapeutics development, with an overview of their active and inactive (dormant or discontinued) projects.
Analysis of Endometriosis Pain drugs under development, considering the stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanisms of action, and molecular type.
In-depth examination of collaborations (both company-to-company and company-to-academia), licensing agreements, and financing details, which are crucial for the future advancement of the Endometriosis Pain market.
The report is compiled using data from proprietary databases, company and university websites, clinical trial registries, conferences, SEC filings, investor presentations, and press releases from company/university websites and industry-specific third-party sources.
Download Sample PDF Report to know more about Endometriosis Pain drugs and therapies
https://www.delveinsight.com/sample-request/endometriosis-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Endometriosis Pain Pipeline Market Drivers
• The development of drug delivery systems represents a new approach in pain treatment among endometriosis patients, extensive research on Non-steroidal anti-inflammatory drugs are some of the important factors that are fueling the Endometriosis Pain Market.
Endometriosis Pain Pipeline Market Barriers
• However, less robust pipeline, high cost of treatment procedures and other factors are creating obstacles in the Endometriosis Pain Market growth.
Scope of Endometriosis Pain Pipeline Drug Insight
• Coverage: Global
• Key Endometriosis Pain Companies: , and others
• Key Endometriosis Pain Therapies: FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others
• Endometriosis Pain Therapeutic Assessment: Endometriosis Pain current marketed and Endometriosis Pain emerging therapies
• Endometriosis Pain Market Dynamics: Endometriosis Pain market drivers and Endometriosis Pain market barriers
Request for Sample PDF Report for Endometriosis Pain Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/endometriosis-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Endometriosis Pain Report Introduction
2. Endometriosis Pain Executive Summary
3. Endometriosis Pain Overview
4. Endometriosis Pain- Analytical Perspective In-depth Commercial Assessment
5. Endometriosis Pain Pipeline Therapeutics
6. Endometriosis Pain Late Stage Products (Phase II/III)
7. Endometriosis Pain Mid Stage Products (Phase II)
8. Endometriosis Pain Early Stage Products (Phase I)
9. Endometriosis Pain Preclinical Stage Products
10. Endometriosis Pain Therapeutics Assessment
11. Endometriosis Pain Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Endometriosis Pain Key Companies
14. Endometriosis Pain Key Products
15. Endometriosis Pain Unmet Needs
16 . Endometriosis Pain Market Drivers and Barriers
17. Endometriosis Pain Future Perspectives and Conclusion
18. Endometriosis Pain Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Biochips Market: https://www.delveinsight.com/report-store/biochips-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Pain Management Devices Market: https://www.delveinsight.com/report-store/pain-management-devices-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-epidemiology-forecast
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Bartonellosis Market: https://www.delveinsight.com/report-store/bartonellosis-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Ocular Motility Disturbance Market: https://www.delveinsight.com/report-store/ocular-motility-disturbance-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Endometriosis Pain Clinical Trials Analysis, 2024: FDA Approvals, Therapies, Pipeline, MOA, ROA and Companies by DelveInsight | FOR 6219, IW-3300, MT-2990, ORIAHNN, Linzagolix, OVAREST, HMI-115, TU2670, OG-6219 here
News-ID: 3520046 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Pain
Enhanced Pain Relief Solutions at Advanced Pain Care
Image: https://www.globalnewslines.com/uploads/2025/03/3f3b6259bfdec02e5dcb7b9d0c838855.jpg
Advanced Pain Care is helping people who suffer from chronic pain with sophisticated, evidence-based treatments. The clinic is particularly focused on non-surgical care that improves the quality of life. With a team of highly qualified pain experts, they work with patients who have back pain, joint pain, and nerve pain.
Personalized Treatment for Every Pain Disorder
Advanced Pain Care offers treatments depending on the cause of pain. Anyone experiencing arthritis, migraine,…
Pain Finisher | Advanced Pain Relief Device
Pain Finisher is an instant pain relief device that is effective on all pains including back pain and knee pain. It is based on the TENS theory of pain management which is easy to use and safe.
By using Pain Finisher, a modern drug-free and non-invasive pain-relieving treatment method, one can get rid of the common pain creams, gels, and risky treatment methods.
So, have a pain-free life with easy-to-use pain relief…
Neuropathic Pain Market: Innovative Therapies Reshaping Chronic Pain Management
In recent years, the global Neuropathic Pain Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Neuropathic Pain Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including…
Visceral Pain Market Analysis 2024: Addressing Pain Management Challenges
The Business Research Company has released its latest global market reports, covering insights for 2024 and offering projections up to 2033.
The Business Research Company presents an extensive market research report on the Visceral Pain Global Market Report 2024, furnishing businesses with a competitive edge through a detailed examination of the market structure, encompassing estimates for various segments and sub-segments.
Furthermore, the report highlights on emerging trends, significant drivers, challenges, and opportunities,…
Global Post-Operative Pain Management Market: Pain Relief Goes Worldwide
Introduction:
The Global Post-Operative Pain Management Market is growing at a rapid pace. This market involves the management of pain after surgical procedures. The market has witnessed significant growth in recent years, owing to the increasing number of surgeries and the rising prevalence of chronic diseases. Pain management is an essential aspect of healthcare, as uncontrolled pain can lead to prolonged hospital stays, delayed recovery, and poor patient outcomes.
In this article,…
Post-Operative Pain Management Market By Type, By Application(Cancer Pain, Arthr …
Global Post-Operative Pain Management Market- Description
Post-operative pain management is predominantly referred to as the use of a wide array of therapies or drugs to reduce muscle and tissue spasm in patients who have recently undergone a surgical procedure. It is evident that all type of surgeries, be it major or minor cause postoperative pain in patients which in turn increases their hospital stays while burdening them with psychological and physical…
